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Abstract
Background: Pseudohypoparathyroidism (PHP) represents a heterogeneous group of rare endocrine disorders
caused by (epi) genetic abnormalities affecting the GNAS locus. It is mainly characterized by resistance to PTH and
TSH, and by peculiar clinical features such as short stature, obesity, cognitive impairment, subcutaneous ossifications
and brachydactyly. Delayed puberty, GHRH and calcitonin resistances have also been described. The healthcare-
pathway recently proposed by the Italian Society of Pediatric Endocrinology and Diabetology (ISPED) has provided
a standardized clinical approach to these conditions. The purpose of the present study was to evaluate its
application in clinical practice, and to collect data for setting future specific studies.
Methods: Through a semi-structured survey, based on the indications of the care-pathway, data on PHP clinical
management were collected. The compilation of each data in the survey was read as an index of the adoption of
the healthcare-pathway in clinical practice.
Results: In addition to the proposing Center, 4 Centers joined the study, thus obtaining a large collection of data
on 48 PHP patients. Highest rates in the completion of data were obtained for diagnostic history, auxological
measurements and subcutaneous ossifications evaluation. As expected, the availability of data for the other
investigated fields was lower, coming from recent research studies. More information has been obtained on
hormonal resistance classically involved in PHP (PTH, TSH, GHRH and GnRH) and on cognitive impairment, while a
few data has been collected on bone mineral status, calcitonin levels and glucolipid metabolism.
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Conclusions: The presented data show that the ISPED healthcare-pathway could represent a valid tool both to
confirm the clinical approach to PHP patients and to allow homogeneous data collection; however, it has not yet
been fully adopted. The strengthening of the network among the major Italian Endocrine Centers will contribute to
improve its application in clinical practice, optimizing the follow-up of these patients and increasing knowledge on
PHP.
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Background
The term Pseudohypoparathyroidism (PHP) identifies a
heterogeneous group of hereditary disorders caused by
(epi) genetic [1] alterations affecting the GNAS locus, on
chromosome 20q13 [2, 3] Within this locus, the hom-
onymous gene encodes for Gsα protein, which is in-
volved in the intracellular signal transduction of multiple
peptide hormone signals and whose altered function ex-
plains the complex clinical manifestations affecting PHP
patients [4]. In particular, these disorders are mainly
characterized by the resistance to biological actions of
the parathyroid hormone, resulting in hypocalcaemia
and hyperphosphataemia, in the presence of high PTH
levels [5]. Resistance to TSH is also frequent and often
represents the first manifestation of the disease, even de-
tected by neonatal screening [6, 7]. Resistance to other
multiple hormones such as GHRH [8–10], GnRH [11],
calcitonin [12] and insulin [13] is variably observed in
PHP patients [14].
The historical classification of PHP differentiated PHP
I from PHP II on the basis of the variation in urinary
cAMP levels after exogenous administration of synthetic
PTH [15, 16], and further distinguished PHP I in type a,
b and c [17], on the basis of hormonal resistances and
the presence of the Albright Hereditary Osteodistrophy
phenotype [18, 19], which includes peculiar physical fea-
tures such as short stature, early onset obesity, round
face, mental retardation, subcutaneous ectopic ossifica-
tions and brachydactyly (Table 1). However, subsequent
studies have highlighted both a clinical and molecular
overlap among the classically described PHP subtypes
[20, 21], therefore a new classification has been proposed
by an European network of experts on PHP. The no-
menclature “Inactivating PTH/PTHrp signalling disor-
ders” (iPPSDs) has been introduced to encompass all the
disorders related to this path [22]. The major criteria
proposed for clinical diagnosis currently include resist-
ance to PTH, ectopic ossifications and brachydactyly.
Minor criteria are represented by resistance to TSH and
other hormonal resistance, motor and cognitive impair-
ment, intrauterine and postnatal growth restriction,
obesity or overweight and facial dysmorphism. Com-
pared to the previous classification based exclusively on
the phenotype, iPPSDs can be further classified from
iPPSD1 to iPPSD6 accordingly to the underlying mo-
lecular (epi) genetic defect, thus achieving an accurate
clinical-molecular definition of each condition (Table 2).
In Italy, the great cooperation among Centers that are
part of the Group of Study “Endocrine diseases due to
Gsα protein impaired function” of the Italian Society of
Pediatric Endocrinology and Diabetology (ISPED) has
led to the drafting of a shared healthcare-pathway [23].
For rare diseases, healthcare-pathways that derive from
the effective and fruitful exchange of experiences among
clinicians, represent important tools for the
standardization of care among Centers. At the same
time, they allow to collect uniform and significant
amount of data, essential to further investigation of the
less studied clinical-molecular aspects, especially in com-
plex and heterogeneous diseases, such as PHP.
The purpose of the present study was to evaluate the
application in clinical practice of the ISPED healthcare-
Table 1 Historical Classification of PHP and PHP-related disorders
AHO Hormone resistance Heterotopic ossification PTH test response GNAS defect




PPHP Yes No Yes, superficial Normal Paternal inactivating mutations
PHP-Ib No PTH, TSH No ↓cAMP
↓phosphaturia
Imprinting dysregulation




POH No No Yes, deep NA Paternal inactivating mutations
Abbreviations: cAMP cyclic AMP; GHRH, GH releasing hormone; PTH parathyroid hormone, TSH thyroid-stimulating hormone, FSH/LH Follicle Stimulating Hormone/
Luteinizing Hormone; POH progressive osseus heteroplasia
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pathway of PHP in the main Italian Centers, to depict
the current state of diagnosis and follow up of PHP, out-
lining any critical issues and providing suggestions for
future improvement. Secondary purpose was to collect
homogeneous data within the ISPED Study Group
“Endocrine diseases due to Gsα protein impaired func-
tion”, to set up subsequent multicenter studies on the
specific clinical aspects of PHP not yet clarified, aimed
at further increasing knowledge about these rare and
complex disorders.
Methods
Based on the ISPED Healthcare-pathway for PHP and
following the indications of the International Consensus
Statement, a semi-structured survey was conceived. To
reach all the Hospitals and University Departments of
Pediatrics scattered throughout the country that deal
with this rare disease, the survey was sent by e-mail to
the clinicians who work in Italian Endocrine Centers
participating to the ISPED Study Group “Endocrine dis-
eases due to Gsα protein impaired function”. Clinicians
were asked to complete the survey with the available
retrospective data of the PHP patients followed between
2010 and 2020 at their Center. After receiving a first
preliminary response, two calls were sent to increase the
reply from Centers and to encourage further data collec-
tion, also highlighting the strength and potential of this
multicenter study. The collected data were analyzed after
one-year period from the first survey release.
In particular, the required data on pregnancy and de-
livery history were aimed at exploring the course of
pregnancy, gestational age and type of birth, APGAR
neonatal score, weight and length. Medical history in-
cluded age at clinical diagnosis and possibly available
molecular confirmation. Auxological parameters (height,
weight and target height) at last visit were requested for
each patient. Resistance to PTH and its complications
were evaluated at diagnosis and at the last control by
looking for serum levels of PTH, calcium, phosphorus,
alkaline phosphatase, the initial therapy, any changes
over time and eventual brain investigation for calcifica-
tions. At least one urinary calcium/creatinine ratio
measurement and one renal US study were required; the
average timing of these evaluations during follow up was
also considered, if available. One assessment of mineral
bone density by Dual-energy X-ray absorptiometry
(DEXA) and/or Quantitative ultrasounds (QUS) was also
requested. Thyroid function analysis included TSH and
thyroid hormone levels at diagnosis and last control, thy-
roid ultrasound study during follow up, and replacement
therapy. The availability of at least one value of calci-
tonin was also investigated. Regarding GHRH resistance,
the survey examined whether GH secretion had been in-
vestigated and whether one IGF1 value was included
during follow up; at least one assessment of bone age
and the chronological age at which it was performed
completed the evaluation. Focusing on GnRH resistance
and gonadal function, age and height at the beginning of
puberty, basal gonadotropins levels and after stimulation,
testosterone values and possible cryptorchidism in
males, 17β-estradiol, age at menarche and regularity of
periods in females were required.
The evaluation of glycolipid metabolism included data
on basal levels and possibly after Oral Glucose Tolerance
Test (OGTT) of glucose and insulin, on glycated
hemoglobin, total and HDL cholesterol and triglycerides,
on blood pressure measurement, on diagnostic or thera-
peutic interventions for any sleep apneas, as well as in-
formation on diet or any treatment and their adherence.
For subcutaneous ossifications, information on num-
ber, time of onset, location, related symptoms, evolution
over time, any diagnostic investigations or adopted ther-
apies was required.
The age of verbal and motor acquisitions, the need for
rehabilitation programs, school or social/psychological
support, as well the evaluation of mental functions with
objective tests, i.e. IQ (Intelligence Quotient), WISC
(Wechsler Intelligence Scale for Children) [24] or WAIS
(Wechsler Adult Intelligence Scale) [25] tests were in-
vestigated to assess neurocognitive development.
Table 2 New Classification and nomenclature of “Inactivating PTH/PTHrP Signalling Disorders” (IPPSDs) – Adapted from Position
Statement EuroPHP Network 2016
iPPSD Molecular Cause Main Features
iPPSD1 Mutations in the coding sequence of PTH1R gene PTH resistance and/or brachydactyly
iPPSD2 Mutations in the coding sequence of GNAS gene
(formerly PHP1A, PHP1C, PPHP/AHO/POH)
PTH resistance and/or subcutaneous ossifications
and/or brachydactyly
iPPSD3 Abnormal methylation at the GNAS A/B:TSS-DMR
(formerly PHP1B)
PTH resistance
iPPSD4 Mutations in the coding sequence of PRKAR1A gene PTH resistance and/or brachydactyly
iPPSD5 Mutations in the coding sequence of PDE4D gene Brachydactyly
iPPSD6 Mutations in the coding sequence of PDE3D gene Brachydactyly +/− hypertension
Abbreviations: iPPSDs Inactivating PTH/PTHrP signaling disorders
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Through a purely descriptive statistical analysis, the
percentage of each data collected from the Centers that
joined the study was calculated for each of the above
listed outcomes. The availability and accuracy in com-
pleting the survey were read and evaluated as an index
adhesion of the Centers to the PHP healthcare-pathway.
The study was approved by the Local Ethics Commit-
tee; in the survey, patients’ data were entered by each
clinician anonymously.
Results
In addition to the proposing Center, other 4 Centers
joined the study, allowing to obtain data on a cohort of
48 patients with PHP.
Data collection rates for the main survey items are
shown in Table 3. These overall results become more
understandable by analyzing the results of the responses
of each specific area (Fig. 1, 2, 3, 4).
Age at clinical diagnosis was indicated in 40 out of 48
patients (83%); mean age at diagnosis was 6.41 years + −
4.51 DS (range 0.17–17 y.o.), while the mean age at
study evaluation was 12.92 years + − 5.84 DS (range
2.17–29.11 y.o).
Data on molecular investigations were available for 35
patients of the entire cohort (73%), even if genetic or
epigenetic definition was indicated for 22 patients out of
these 35 patients (63%): GNAS gene mutations have
been reported in 19 (86% PHP-Ia/Ic), metilation GNAS
defects in 2 (PHP-Ib 9%) and PDE4D mutations in 1 out
of the 22 patients (5%).
Gestational age and type of delivery were reported in
32 and 31 patients (67 and 65%), respectively, but infor-
mation on the course of pregnancy was not available in
nearly half cohort (23/48, 48%); in 30 patients (62%)
APGAR score was missing, while the availability of
neonatal measurements was discordant, as weight was
reported for 36 (75%), while length for 24 (50%) patients.
Non physiological pregnancy was described in 8/25 pa-
tients (32%), preterms before 37 weeks of pregnancy in
5/32 patients (16%), delivery impairment in 12/31 pa-
tients (39%), 7/36 patients were small for gestational age
(19%), 2/36 patients were large for gestational age (6%),
Apgar score was equal/low than 7 in 4/18 patients
(22%).
Focusing on PTH resistance, complete data on
calcium-phosphorus metabolism evaluation were re-
corded in half patients at diagnosis and last control;
however, by excluding ALP investigations, these rates in-
creased to 75% (36/48) and 73% (35/48) at diagnosis and
last control, respectively. The evaluation of the mineral
bone state was missing in over half of the patients (28/
48), while at least one urinary calcium/creatinine ratio
was available in 30 patients, although monitoring of this
parameter was reported only in 18 patients. Interest-
ingly, excluding both measurement of ALP and bone
mineral status, the percentage of data completion on
calcium-phosphorus metabolism increased from 17 to
50%. Initial therapy was reported in almost all cases,
while less information was available on any therapeutic
changes at last check-up. Data on renal ultrasound were
more available rather than on brain imaging (Fig.1). For
calcitonin levels, data were missing for most of the co-
hort patients (38/48).
As regards resistance to TSH and thyroid function,
TSH and FT4 values were collected in 32 patients at
diagnosis but in only 16 at the last control; the ultra-
sound study on the thyroid gland was available for 34
patients. Initial replacement therapy and eventual thera-
peutic changes at the last control were reported for 37
and 30 patients, respectively.
Table 3 Data collection rates for the main items of the survey
Outcomes Data collection
Complete Partial Absent
Diagnostic history 69% 19% 12%
Pregnancy and delivery history 21% 54% 25%
PTH resistance and calcium-phosphorus metabolism 17% 79% 4%
Kidney and brain calcifications 36% 58% 6%
TSH resistance and thyroid function 21% 71% 8%
Calcitonin resistance 21% / 79%
GHRH resistance 31% 44% 25%
GnRH resistance and gonadal function 50% 31% 19%
Auxological parameters 60% 30% 10%
Glycolipid metabolism 19% 69% 12%
Subcutaneous ossifications 69% 17% 14%
Neurocognitive development 27% 54% 19%
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In the evaluation of GHRH resistance, GH secretion
after stimulus was studied in one third of the patients,
IGF1 measured in more than half and bone age available
for about half patients. For GnRH resistance and go-
nadal function assessment, hormonal evaluations were
reported for almost half patients, cryptorchidism was re-
corded in the majority of males, while age at menarche
and regularity of periods in 9 and 6 out of 14 subjects
who had already had menarche, respectively. Age and
height at the beginning of puberty were available in 14
out 35 pubertal patients (Fig.2).
Auxological parameters of height and weight were ac-
curately reported in most of cases, whereas data on tar-
get height were lacking in almost one third of patients.
Glycolipid metabolism data were fully provided in 9
patients of the total cohort: glucose levels and lipids
assessment, was reported in the majority of patients, un-
like insulin and glycated hemoglobin levels mostly miss-
ing. Blood pressure parameters were available for one
third of patients, while data on adherence to diet and
obesity treatments or any diagnostic or therapeutic in-
terventions in case of sleep apnea for about half of the
patients (Fig. 3).
The study of subcutaneous ossifications was re-
ported for the majority of cohort subjects (85% of
cases) and these lesions were detected in 15/48 pa-
tients; for all, data on the number, time of onset and
location were available, while related symptoms and
evolution over time were reported in 10/15 and 7/15
patients, respectively. Any diagnostic investigations
and therapies were indicated in 11/15 and in 8/15
cases, respectively.
Fig. 1 Calcium-phosphorus impairment evaluation
Fig. 2 GHRH and GnRH resistance evaluation
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Finally, to define the neurocognitive development
study, data on the age of verbal and motor acquisitions
were obtained in 27 patients, and for 20 patients the cli-
nicians specified if objective tests for the assessment of
mental functions were performed. The need of rehabili-
tation programs was indicated for 36 patients, scholastic
and social/psychological support for 33 and 27 patients,
respectively (Fig.4).
Discussion
This is a national multicenter study in which the appli-
cation of the healthcare pathway on PHP issued by Ital-
ian Society of Pediatric Endocrinology and Diabetology
(ISPED) [23] was investigated. The main Italian Centers
of reference for this rare disease participated in the
study, with the attempt to define the current status of
the diagnostic path and follow-up of patients with PHP
in each center, to make it homogeneous among Centers
and to investigate which aspects need to be improved. In
general, the collected data show that most of the indica-
tions of the path on the diagnosis and management of
patients with PHP are already part of normal clinical
practice, in particular those relating to aspects that have
long been known in the literature; for other more recent
aspects, greater attention and homogeneity of behavior
among Centers is required. For still others, to be consid-
ered as a starting point for future researches, the collec-
tion of multicenter data will allow to verify their real
value for diagnosis or follow up.
The lack of some responses to the survey has to be
interpreted as a normal difference among the Centers
and a normal updating process of clinical practice not
yet completed for this complex disease. The fact that
few Centers took part in the survey confirms the low in-
cidence of the disease, whose management remains the
prerogative of some centers with experience over time,
Fig. 3 Auxological parameters and glycolipid metabolism
Fig. 4 Neurocognitive development
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as occurs for most rare diseases and as indicated by all
the main international networks that deal with rare dis-
eases. After the publication of diagnostic-therapeutic
pathways, their application to the clinical practice is
often not investigated. The real sharing of the ISPED
diagnostic-therapeutic path on PHP among expert Ital-
ian Centers will facilitate the creation of a homogeneity
in the management of the disease, which can subse-
quently be transferred also to less experienced Centers
for homogeneous treatment even near the residence of
each patient.
Despite the participation of a few Centers in the study,
the survey allowed to collect a large number of data on
48 subjects affected by PHP, which represent a consider-
able case series, useful for future investigations.
Taking into consideration the different aspects of the
disease investigated, it is important to make some clarifi-
cations and comments. The collection of data was
complete in the majority of patients on only three as-
pects, namely diagnostic history, auxological measure-
ments and evaluation of subcutaneous ossifications,
which represent the first medical actions at the basis of
taking charge of a subject with this rare disease and one
of the most specific parameters for the clinical suspicion
of the disease [14, 22], easy to identify and monitor over
time. Noteworthy is the high rate of confirmation of the
molecular diagnosis, the importance of which is well
known to the reference Centers, for a complete diagnos-
tic definition, more specific follow-up over time and ad-
equate genetic counseling for risk assessment of the
recurrence of the disease in the family.
Conversely, data on pregnancy and childbirth were
partial or even absent, but it would important to collect
them, since to date the only data available concern
weight and length at birth, which appear to be different
between PHP-Ia and Ib [14]; such data could be
regarded as an early diagnostic handle for guiding the
most specific molecular analysis.
Although calcium-phosphorus metabolism is probably
the most studied aspect in the literature, some new as-
pects have not yet entered in the normal clinical prac-
tice, such as bone mineral density, whose trend is not
fully known in PHP subjects [26].
Data on imaging showed that renal ultrasound control
has been reserved mainly to patients with persistent hy-
percalciuria or specific clinical indications, since PHP
seems to less associated to kidney calcification than
other conditions [14, 23], while brain investigation has
been conducted in few patients, as currently indicated,
only in case of neurological manifestations [14].
Data on thyroid function were not always present,
while it is well known that it should be measured from
the first diagnostic suspicion of PHP, as resistance to
TSH often represents the first hormonal resistance that
appears, already detectable at neonatal screening [7, 26],
and should be monitored over time for the correct ad-
justments of the replacement therapy and to follow its
evolution throughout life; as well as the possible resist-
ance to GHRH should be earlier identified, in order to
obtain better growth gain with hrGH treatment before
the premature closure of the growth cartilages typical of
these subjects [8–10, 14].
From the study of calcitonin, interesting data will
come on the prevalence and symptoms related to its re-
sistance and the evolution over time, useful to indicate
the correct timing for its investigation and monitoring;
on the other hand, data collection on GnRH resistance,
on the neurocognitive impairment, on glucose-lipid me-
tabolism and blood pressure in a wide serie of PHP sub-
jects will improve their management even after the
transition of care to adulthood [13, 27].
Overall, new studies following the extensive applica-
tion of this common healthcare pathway for the iPPDs
could further elucidate differences or overlaps between
the different subtypes [14].
Conclusions
In conclusion, the present study had the main purpose
of investigating the clinical application to the national
care-pathway indications. However, thanks to the deep
collaboration among centers within the ISPED Group of
Study, huge amount of clinical data have been obtained
for each specific aspect of PHP, useful for future multi-
center studies. Thus, for rare diseases, the creation and
the adoption of a shared care pathway could have posi-
tive effects not only in improving patients’ assistance,
but also in increasing the disease knowledge.
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